U.S. stocks traded higher, with the Dow Jones gaining around 100 points on Thursday. Here are some big stocks recording gains in today’s session.
- ShiftPixy, Inc. (NASDAQ: PIXY) shares surged 73.8% to $19.48 after the company announced plans to spin-off ShiftPixy Labs and dividend its digital securities to shareholders.
- Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) surged 64% to $29.35 after the FDA Advisory Committee voted that available evidence of effectiveness is sufficient to support approval of AMX0035 for the treatment of ALS. Citigroup (NYSE:C) and SVB Leerink raised their price targets.
- Asana, Inc. (NYSE: ASAN) shares gained 21% to $23.03 after the company reported better-than-expected results for its second quarter and issued a strong sales guidance. RBC Capital and Citigroup raised their price targets on the stock.
- Relay Therapeutics, Inc. (NASDAQ: RLAY) surged 19.9% to $30.40. Relay Therapeutics announced efficacy of RLY-4008, a highly selective FGFR2 inhibitor in patients with a FGFR2-fusion or rearrangement FGFR inhibitor-naïve cholangiocarcinoma: ReFocus trial.
- LifeStance Health Group, Inc. (NASDAQ: LFST) gained 17.6% to $8.95. LifeStance Health named Ken Burdick as CEO and Chairman.
- AeroVironment, Inc. (NASDAQ: AVAV) gained 15.3% to $102.20 after reporting upbeat quarterly sales.
- Eve Holding, Inc. (NYSE: EVEX) surged 14.8% to $7.07. United reported a $15 million investment in Eve Air Mobility and a conditional purchase agreement for 200 four-seat electric aircraft plus 200 options.
- Cazoo Group Ltd (NYSE: CZOO) surged 14.7% to $0.70. The company announced it will wind down operations in mainland Europe to focus on core UK market
- Rhythm Pharmaceuticals, Inc. (NASDAQ: RYTM) gained 14.6% to $23.90. Rhythm Pharmaceuticals announced new employment inducement grants. Goldman Sachs (NYSE:GS) maintained Rhythm Pharmaceuticals with a Buy and raised the price target from $28 to $31.
- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) gained 14.1% to $680.56 after the company announced that the primary endpoints were met in two pivotal trials investigating novel aflibercept 8 mg with 12- and 16-week dosing regimens in patients with diabetic macular edema and wet age-related macular degeneration.
- Phreesia, Inc. (NYSE: PHR) gained 13.6% to $27.19 after the company reported better-than-expected Q2 sales results and raised the low-end of its FY23 sales guidance.
- Intapp, Inc. (NASDAQ: INTA) gained 12.4% to $16.52 after the company reported better-than-expected Q4 results and issued guidance above estimates.
- Albireo Pharma, Inc. (NASDAQ: ALBO) surged 11% to $18.50. Guggenheim initiated coverage on Albireo Pharma with a Buy rating and announced a price target of $55.
- Lyft , Inc. (NASDAQ: NASDAQ:LYFT) gained 10.5% to $16.25 amid vague rumors from a questionable source mentioning the company.
- Athersys, Inc. (NASDAQ: ATHX) rose 9.7% to $2.38.
- IVERIC bio, Inc. (NASDAQ: ISEE) rose 8.8% to $16.24. Stifel maintained IVERIC bio with a Buy and raised the price target from $28 to $35.
- Snap Inc . (NYSE: NYSE:SNAP) rose 7.3% to $12.29 on continued strength after a recent internal memo obtained by The Verge suggested the company is aiming to reach $6 billion in revenue and 450 million users by next year.
- GameStop Corp . (NYSE: NYSE:GME) rose 7% to $25.72 after the company reported better-than-expected earnings for its second quarter and also announced a partnership with cryptocurrency exchange FTX to bring more customers to the digital asset space.
- Zillow Group, Inc. (NASDAQ: ZG) gained 6.9% to $37.80 after Jefferies maintained a Buy rating on the stock and raised its price target from $48 to $50.
3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or
remove ads
.
Read at Benzinga